Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Mortality in COPD: role of comorbidities

D. D. Sin, N. R. Anthonisen, J. B. Soriano, A. G. Agusti
European Respiratory Journal 2006 28: 1245-1257; DOI: 10.1183/09031936.00133805
D. D. Sin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. R. Anthonisen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. B. Soriano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. G. Agusti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic obstructive pulmonary disease (COPD) represents an increasing burden throughout the world. COPD-related mortality is probably underestimated because of the difficulties associated with identifying the precise cause of death. Respiratory failure is considered the major cause of death in advanced COPD. Comorbidities such as cardiovascular disease and lung cancer are also major causes and, in mild-to-moderate COPD, are the leading causes of mortality.

The links between COPD and these conditions are not fully understood. However, a link through the inflammation pathway has been suggested, as persistent low-grade pulmonary and systemic inflammation, both known risk factors for cardiovascular disease and cancer, are present in COPD independent of cigarette smoking.

Lung-specific measurements, such as forced expiratory volume in one second (FEV1), predict mortality in COPD and in the general population. However, composite tools, such as health-status measurements (e.g. St George's Respiratory Questionnaire) and the BODE index, which incorporates Body mass index, lung function (airflow Obstruction), Dyspnoea and Exercise capacity, predict mortality better than FEV1 alone. These multidimensional tools may be more valuable because, unlike predictive approaches based on single parameters, they can reflect the range of comorbidities and the complexity of underlying mechanisms associated with COPD.

The current paper reviews the role of comorbidities in chronic obstructive pulmonary disease mortality, the putative underlying pathogenic link between chronic obstructive pulmonary disease and comorbid conditions (i.e. inflammation), and the tools used to predict chronic obstructive pulmonary disease mortality.

  • Chronic obstructive pulmonary disease
  • comorbidities
  • inflammation
  • mortality

Footnotes

    • © ERS Journals Ltd
    View Full Text
    PreviousNext
    Back to top
    View this article with LENS
    Vol 28 Issue 6 Table of Contents
    European Respiratory Journal: 28 (6)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Mortality in COPD: role of comorbidities
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Mortality in COPD: role of comorbidities
    D. D. Sin, N. R. Anthonisen, J. B. Soriano, A. G. Agusti
    European Respiratory Journal Dec 2006, 28 (6) 1245-1257; DOI: 10.1183/09031936.00133805

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Mortality in COPD: role of comorbidities
    D. D. Sin, N. R. Anthonisen, J. B. Soriano, A. G. Agusti
    European Respiratory Journal Dec 2006, 28 (6) 1245-1257; DOI: 10.1183/09031936.00133805
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • CASE DEFINITION OF COMORBIDITY
      • MEASUREMENTS OF COMORBIDITIES IN COPD
      • THE TWO MOST IMPORTANT COMORBIDITIES IN COPD MORTALITY: CANCER AND CARDIOVASCULAR DISEASES
      • LIMITATIONS IN ATTRIBUTING CAUSES OF DEATH IN COPD PATIENTS
      • SYSTEMIC AND PULMONARY INFLAMMATION: THE MECHANISTIC LINK BETWEEN COPD AND CANCER AND CARDIOVASCULAR DISEASE?
      • RELATIONSHIP BETWEEN COPD AND LUNG CANCER
      • RELATIONSHIP BETWEEN COPD AND CARDIOVASCULAR DISEASE
      • COMORBIDITIES AND COPD MORTALITY: CAUSE OR EFFECT?
      • PREDICTING MORTALITY IN PATIENTS WITH COPD
      • IMPLICATIONS FOR FUTURE RESEARCH
      • CONCLUSIONS
      • Acknowledgments
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • The pathophysiological role of novel pulmonary arterial hypertension gene SOX17
    • Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
    • When things go wrong: Exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases
    Show more Review

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • CME
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2021 by the European Respiratory Society